| Year of Transplant | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | ||
| Functioning Graft at Discharge | 127 | 113 | 151 | 169 | 141 | 170 | 181 | 152 | 187 | 202 | |
| With Immunosuppression Info | 126 | 113 | 150 | 169 | 139 | 169 | 181 | 151 | 185 | 201 | |
| Corticosteroids | Any in Category | 71.4% | 78.8% | 77.3% | 69.2% | 53.2% | 49.7% | 51.9% | 51.7% | 57.8% | 56.7% |
| Steroids | 71.4% | 78.8% | 77.3% | 69.2% | 53.2% | 49.7% | 51.9% | 51.7% | 57.8% | 56.7% | |
| Cyclosporine | Any in Category | 2.4% | 4.4% | 4.0% | 3.6% | 2.2% | 1.2% | 0.0% | 2.0% | 2.2% | 1.5% |
| Sandimmmune | 0.0% | 0.0% | 1.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.7% | 0.5% | 0.0% | |
| Neoral | 2.4% | 4.4% | 2.7% | 3.6% | 2.2% | 1.2% | 0.0% | 1.3% | 1.6% | 1.5% | |
| Tacrolimus | Any in Category | 95.2% | 92.9% | 94.7% | 95.3% | 82.7% | 75.7% | 92.3% | 95.4% | 95.1% | 97.5% |
| Tacrolimus | 95.2% | 92.9% | 94.7% | 95.3% | 82.7% | 75.7% | 92.3% | 95.4% | 95.1% | 97.5% | |
| Antimetabolites | Any in Category | 64.3% | 69.0% | 62.0% | 59.8% | 59.7% | 60.4% | 57.5% | 54.3% | 59.5% | 62.2% |
| Mycophenolate Mofetil | 64.3% | 67.3% | 60.7% | 58.0% | 59.7% | 59.2% | 54.7% | 50.3% | 51.9% | 55.7% | |
| Mycophenolate Sodium | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.8% | 4.0% | 5.9% | 6.0% | |
| Azathioprine | 0.0% | 1.8% | 1.3% | 1.8% | 0.0% | 1.2% | 0.0% | 0.0% | 1.6% | 0.5% | |
| mTOR Inhibitors | Any in Category | 1.6% | 8.0% | 9.3% | 15.4% | 17.3% | 11.2% | 14.9% | 25.2% | 16.8% | 10.9% |
| Sirolimus | 1.6% | 8.0% | 9.3% | 15.4% | 17.3% | 11.2% | 14.9% | 25.2% | 16.8% | 10.9% | |
| Everolimus | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |